vs
Side-by-side financial comparison of CACI INTERNATIONAL INC (CACI) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
CACI INTERNATIONAL INC is the larger business by last-quarter revenue ($2.2B vs $1.2B, roughly 1.9× Jazz Pharmaceuticals plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs 5.6%, a 11.4% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs 5.7%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $138.2M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 7.0%).
CACI International Inc is a U.S.-headquartered multinational professional services and information technology firm. It delivers custom technology solutions, cybersecurity services, data analytics, and mission-critical operational support to government defense, intelligence, civilian agencies, and select private sector clients.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
CACI vs JAZZ — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $1.2B |
| Net Profit | $123.9M | $203.5M |
| Gross Margin | — | — |
| Operating Margin | 9.3% | 21.2% |
| Net Margin | 5.6% | 17.0% |
| Revenue YoY | 5.7% | 10.1% |
| Net Profit YoY | 12.7% | 6.5% |
| EPS (diluted) | $5.59 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $1.2B | ||
| Q3 25 | $2.3B | $1.1B | ||
| Q2 25 | $2.3B | $1.0B | ||
| Q1 25 | $2.2B | $897.8M | ||
| Q4 24 | $2.1B | $1.1B | ||
| Q3 24 | $2.1B | $1.1B | ||
| Q2 24 | $2.0B | $1.0B | ||
| Q1 24 | $1.9B | $902.0M |
| Q4 25 | $123.9M | $203.5M | ||
| Q3 25 | $124.8M | $251.4M | ||
| Q2 25 | $157.9M | $-718.5M | ||
| Q1 25 | $111.9M | $-92.5M | ||
| Q4 24 | $109.9M | $191.1M | ||
| Q3 24 | $120.2M | $215.1M | ||
| Q2 24 | $134.7M | $168.6M | ||
| Q1 24 | $115.3M | $-14.6M |
| Q4 25 | 9.3% | 21.2% | ||
| Q3 25 | 9.3% | 5.1% | ||
| Q2 25 | 9.0% | -65.6% | ||
| Q1 25 | 9.1% | -6.2% | ||
| Q4 24 | 8.6% | 17.5% | ||
| Q3 24 | 8.7% | 24.7% | ||
| Q2 24 | 9.7% | 19.5% | ||
| Q1 24 | 9.4% | 7.3% |
| Q4 25 | 5.6% | 17.0% | ||
| Q3 25 | 5.5% | 22.3% | ||
| Q2 25 | 6.9% | -68.7% | ||
| Q1 25 | 5.2% | -10.3% | ||
| Q4 24 | 5.2% | 17.6% | ||
| Q3 24 | 5.8% | 20.4% | ||
| Q2 24 | 6.6% | 16.5% | ||
| Q1 24 | 6.0% | -1.6% |
| Q4 25 | $5.59 | $3.34 | ||
| Q3 25 | $5.63 | $4.08 | ||
| Q2 25 | $7.11 | $-11.74 | ||
| Q1 25 | $5.00 | $-1.52 | ||
| Q4 24 | $4.88 | $2.97 | ||
| Q3 24 | $5.33 | $3.42 | ||
| Q2 24 | $5.97 | $2.49 | ||
| Q1 24 | $5.13 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $423.0M | $1.4B |
| Total DebtLower is stronger | $3.0B | $5.4B |
| Stockholders' EquityBook value | $4.1B | $4.3B |
| Total Assets | $8.9B | $11.7B |
| Debt / EquityLower = less leverage | 0.72× | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $423.0M | $1.4B | ||
| Q3 25 | $133.0M | $1.3B | ||
| Q2 25 | $106.2M | $1.2B | ||
| Q1 25 | $223.9M | $1.9B | ||
| Q4 24 | $175.7M | $2.4B | ||
| Q3 24 | $440.7M | $2.2B | ||
| Q2 24 | $134.0M | $1.4B | ||
| Q1 24 | $159.2M | $1.4B |
| Q4 25 | $3.0B | $5.4B | ||
| Q3 25 | $2.8B | $5.4B | ||
| Q2 25 | $2.9B | $5.4B | ||
| Q1 25 | $3.1B | $5.4B | ||
| Q4 24 | $3.1B | $6.1B | ||
| Q3 24 | $1.8B | $6.1B | ||
| Q2 24 | $1.5B | $5.7B | ||
| Q1 24 | $1.7B | $5.7B |
| Q4 25 | $4.1B | $4.3B | ||
| Q3 25 | $4.0B | $4.0B | ||
| Q2 25 | $3.9B | $3.7B | ||
| Q1 25 | $3.7B | $4.2B | ||
| Q4 24 | $3.7B | $4.1B | ||
| Q3 24 | $3.7B | $4.2B | ||
| Q2 24 | $3.5B | $3.8B | ||
| Q1 24 | $3.4B | $3.7B |
| Q4 25 | $8.9B | $11.7B | ||
| Q3 25 | $8.7B | $11.4B | ||
| Q2 25 | $8.6B | $10.9B | ||
| Q1 25 | $8.6B | $11.5B | ||
| Q4 24 | $8.5B | $12.0B | ||
| Q3 24 | $7.2B | $12.3B | ||
| Q2 24 | $6.8B | $11.4B | ||
| Q1 24 | $6.8B | $11.3B |
| Q4 25 | 0.72× | 1.24× | ||
| Q3 25 | 0.69× | 1.35× | ||
| Q2 25 | 0.75× | 1.45× | ||
| Q1 25 | 0.84× | 1.29× | ||
| Q4 24 | 0.82× | 1.49× | ||
| Q3 24 | 0.50× | 1.47× | ||
| Q2 24 | 0.44× | 1.52× | ||
| Q1 24 | 0.50× | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $154.2M | $362.5M |
| Free Cash FlowOCF − Capex | $138.2M | $345.8M |
| FCF MarginFCF / Revenue | 6.2% | 28.9% |
| Capex IntensityCapex / Revenue | 0.7% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.24× | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | $634.3M | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $154.2M | $362.5M | ||
| Q3 25 | $171.1M | $474.6M | ||
| Q2 25 | $156.0M | $88.9M | ||
| Q1 25 | $230.3M | $429.8M | ||
| Q4 24 | $126.0M | $398.6M | ||
| Q3 24 | $34.7M | $398.7M | ||
| Q2 24 | $157.2M | $331.4M | ||
| Q1 24 | $198.3M | $267.2M |
| Q4 25 | $138.2M | $345.8M | ||
| Q3 25 | $154.1M | $459.4M | ||
| Q2 25 | $128.0M | $75.9M | ||
| Q1 25 | $214.1M | $415.9M | ||
| Q4 24 | $116.1M | $385.3M | ||
| Q3 24 | $23.2M | $388.0M | ||
| Q2 24 | $134.6M | $324.3M | ||
| Q1 24 | $186.6M | $260.3M |
| Q4 25 | 6.2% | 28.9% | ||
| Q3 25 | 6.7% | 40.8% | ||
| Q2 25 | 5.6% | 7.3% | ||
| Q1 25 | 9.9% | 46.3% | ||
| Q4 24 | 5.5% | 35.4% | ||
| Q3 24 | 1.1% | 36.8% | ||
| Q2 24 | 6.6% | 31.7% | ||
| Q1 24 | 9.6% | 28.9% |
| Q4 25 | 0.7% | 1.4% | ||
| Q3 25 | 0.7% | 1.3% | ||
| Q2 25 | 1.2% | 1.2% | ||
| Q1 25 | 0.7% | 1.5% | ||
| Q4 24 | 0.5% | 1.2% | ||
| Q3 24 | 0.6% | 1.0% | ||
| Q2 24 | 1.1% | 0.7% | ||
| Q1 24 | 0.6% | 0.8% |
| Q4 25 | 1.24× | 1.78× | ||
| Q3 25 | 1.37× | 1.89× | ||
| Q2 25 | 0.99× | — | ||
| Q1 25 | 2.06× | — | ||
| Q4 24 | 1.15× | 2.09× | ||
| Q3 24 | 0.29× | 1.85× | ||
| Q2 24 | 1.17× | 1.97× | ||
| Q1 24 | 1.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CACI
| Service Other | $876.3M | 39% |
| Intelligence Community | $539.0M | 24% |
| Federal Civilian Agencies | $438.6M | 20% |
| Subcontractor | $202.5M | 9% |
| Other | $148.5M | 7% |
| Commercial And Other | $15.2M | 1% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
